Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 1998, p. 2823-2827, Vol. 36, No. 10
Department of Entomology, The Connecticut
Agricultural Experiment Station, New Haven, Connecticut
065041;
Section of Rheumatology,
Received 30 December 1997/Returned for modification 14 May
1998/Accepted 30 June 1998
Indirect fluorescent-antibody (IFA) staining methods with
Ehrlichia equi (MRK or BDS strains) and Western blot
analyses containing a human granulocytic ehrlichiosis (HGE) agent
(NCH-1 strain) were used to confirm probable human cases
of infection in Connecticut during 1995 and 1996. Also included were
other tests for Ehrlichia chaffeensis, the agent of human
monocytic ehrlichiosis (HME), Babesia microti, and
Borrelia burgdorferi. Thirty-three (8.8%) of 375 patients who had fever accompanied by marked leukopenia or
thrombocytopenia were serologically confirmed as having HGE. Western blot analyses of a subset of positive sera confirmed the results of the IFA staining methods for 15 (78.9%) of 19 seropositive specimens obtained from different persons. There was frequent detection of antibodies to a 44-kDa protein of the HGE agent. Serologic
testing also revealed possible cases of Lyme borreliosis (n = 142), babesiosis (n = 41), and
HME (n = 21). Forty-seven (26.1%) of 180 patients had
antibodies to two or more tick-borne agents. Therefore, when one of
these diseases is clinically suspected or diagnosed, clinicians
should consider the possibility of other current or past tick-borne
infections.
Ticks are abundant in or near
forested areas of southern New England. Human granulocytic ehrlichiosis
(HGE), a recently described tick-associated disease, occurs there and
in the upper midwestern United States (29). Illnesses can be
mild or severe. In patients with severe illness, there is usually
marked thrombocytopenia, leukopenia, and elevations in serum
aminotransferase concentrations (4, 28). Although infections
can sometimes be fatal (4, 28, 29), prompt clinical
diagnosis and antibiotic therapy effectively reduce morbidity and
mortality.
The etiologic agent of HGE (an unnamed organism) in the United States
is very closely related, with at least 99.8% homology (5),
to Ehrlichia equi and Ehrlichia phagocytophila,
veterinary pathogens widely distributed in the United States and
Europe. On the basis of 16S rRNA gene analyses (5, 6, 29),
E. equi and E. phagocytophila are
nearly identical (99.8% homology); these organisms and the HGE agent
are considered to be members of the E. phagocytophila
genogroup. The suspected tick vectors of the HGE agent are Ixodes
scapularis in the eastern and upper midwestern United States and
Ixodes pacificus in western states (29).
Ixodes ricinus, a closely related tick species, transmits E. phagocytophila, the causative agent of tick-borne
fever in cattle and sheep in Europe. Following the application of PCR
methods, the DNA of the HGE agent has been detected in I. scapularis ticks in Connecticut (19), Massachusetts
(27), Rhode Island (31), and Wisconsin
(23). Moreover, clinical and serological findings indicate
that HGE occurs in areas where these ticks and infections of human
babesiosis and Lyme borreliosis have been reported (12, 17, 27,
28, 30). There is growing evidence of human exposure to multiple
tick-borne pathogens in areas where I. scapularis ticks
abound.
Indirect fluorescent-antibody (IFA) staining methods are being used
extensively to detect antibodies to the HGE agent. However, little is
known about the accuracy of these procedures or the prevalence of
infection with or without the presence of other tick-borne
pathogens, such as Ehrlichia chaffeensis, Borrelia burgdorferi, and Babesia microti. The present study was
conducted to (i) analyze sera from persons who were strongly suspected
by physicians as having HGE and to determine the prevalence of
infection, (ii) compare the results of IFA staining methods with those
of Western blot analysis for the detection of antibodies to
E. equi and the HGE agent, respectively, and (iii)
determine if sera positive for HGE antibodies also contain
immunoglobulins to E. chaffeensis, B. burgdorferi, and B. microti.
Serum specimens.
As a part of a statewide surveillance
program on emerging infectious diseases, physicians obtained 512 serum
specimens from 375 persons who lived in or who had entered
tick-infested areas of Connecticut and who had acute febrile
illnesses with headache and myalgias. Accompanying clinical
records indicated leukopenia or thrombocytopenia for all subjects.
Therefore, all sera were from patients who were clinically suspected of
having HGE. Sera were obtained 5 to 515 days after the onset of
illness during 1995 and 1996. There were 254 samples from 117 persons
available for determination of changes in antibody titers (i.e.,
seroconversions and reversions). Specimens were sent from the
Connecticut Department of Health to the Connecticut Agricultural
Experiment Station for analyses.
Serologic testing for HGE.
IFA staining methods and
Western blot analysis were used to detect total or class-specific
immunoglobulins to E. equi and the HGE agent,
respectively. The former has been successfully used as a surrogate
antigen for the laboratory diagnosis of HGE (4, 6, 30). The
antigen-coated slides used in IFA assays were purchased from John
Madigan of the University of California (Davis, Calif.) and contained
horse neutrophils infected with E. equi (the MRK or BDS
strain). Sera were diluted in phosphate-buffered saline (PBS) solutions
(pH 7.2) and were tested for total antibodies with a 1:80 dilution of
polyvalent fluorescein isothiocyanate-labeled goat anti-human
immunoglobulin (Ig) (Organon Teknika Corp., Durham, N.C.). To detect
class-specific antibodies, commercially prepared goat anti-human IgM
(µ-chain-specific) and goat anti-human IgG ( Serologic testing for babesiosis and Lyme borreliosis.
An
IFA staining procedure (17) was used to detect total
antibodies to B. microti, while polyvalent and
class-specific ELISAs were used to quantitate the concentrations of
antibodies to B. burgdorferi sensu stricto (strain
2591) in serum. Whole cells of this spirochete were coated onto
polystyrene plates for a polyvalent ELISA used for the screening of
sera. Purified preparations of the following recombinant antigens of
B. burgdorferi were used to confirm polyvalent assay
results and to detect IgM or IgG antibodies: outer surface protein
(Osp) OspC, OspE, OspF, and p41-G (the 13-kDa central fragment of
flagellin). When available, paired sera were analyzed to document
seroconversions and reversions. Details on the production of antigens,
sources of conjugates and control sera, and the sensitivities and
specificities of these assays have been reported previously (14,
15, 17, 18).
Specificity tests.
Tests on the specificity of the IFA
staining methods have been conducted with homologous and heterologous
antigens and antisera of ehrlichiae, such as E. canis,
E. chaffeensis, E. equi, and E. risticii (17, 19). Although there was no
evidence of cross-reactivity between E. equi and
E. chaffeensis in these tests and there are no reports
of the DNA of the latter being detected in human or tick tissues in
Connecticut, all sera were tested by IFA staining methods for
E. chaffeensis antibodies as done before
(17). Further analyses of human sera were needed to
determine if the banding patterns associated with B. burgdorferi infections in immunoblots overlap with those
characteristic of HGE. A peptide of E. equi and
isolates of the HGE agent with a molecular mass of about 44 kDa appears
to be a suitable indicator of HGE infection (6, 10, 11, 24,
29) because it is frequently reactive in Western blot analysis
and has a high degree of specificity. Accordingly, five coded serum
specimens from persons who had erythema migrans and IgM and IgG
antibodies to whole B. burgdorferi cells
(14) were screened by immunoblotting methods with lysates of
the NCH-1 strain of the HGE agent. These patients had no history of
leukopenia or thrombocytopenia, and their sera were negative by IFA
staining methods for antibodies to E. equi. In
addition, five serum specimens from syphilitic patients and five serum
specimens from persons diagnosed with rheumatoid arthritis, which had
been tested in another study (14), were included in the
analyses to assess specificity.
There were antibodies to E. equi in 50 (9.8%) of
512 serum specimens tested by IFA staining methods. The titration
endpoints ranged from 1:80 to 1:5,120 (Table
1). A comparison of geometric means
revealed at least a threefold higher value for sera tested by an
ELISA for Lyme borreliosis compared to those calculated for HGE,
human monocytic ehrlichiosis (HME), and babesiosis by IFA
staining methods.
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Human Exposure to a Granulocytic Ehrlichia and
Other Tick-Borne Agents in Connecticut
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-chain-specific)
reagents (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) were
diluted in PBS solutions to 1:40 and 1:20, respectively. The
reactivities of these conjugates were verified by testing a panel of
control sera from persons who had Lyme borreliosis and in whom
immunoblotting or enzyme-linked immunosorbent assay (ELISA) procedures
had confirmed the presence of IgM or IgG antibodies. Further details on
IFA staining methods and sources of positive and negative control sera
for HGE are reported elsewhere (17). Distinct fluorescence
of inclusion bodies (morulae) in infected neutrophils was considered
evidence of antibody presence in sera diluted to 1:80 or greater. There
were no false-positive reactions when sera from healthy persons (i.e.,
negative controls) were tested at this dilution. Grading of
fluorescence was done conservatively. Serial dilutions of all positive
sera were retested to determine titration endpoints.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
TABLE 1.
Reactivities to E. equi, E. chaffeensis, B. microti, and B. burgdorferi for persons who had leukopenia or thrombocytopenia and
whose sera were collected in Connecticut during 1995 and 1996
Serologic results (Table 2) indicated more cases of Lyme borreliosis (n = 142) than babesiosis (n = 41), HGE (n = 33), or HME (n = 21). The age distribution for all 375 patients was 2 to 96 years, whereas the ages of persons confirmed to have HGE ranged from 16 to 81 years. The median ages for each group were 53 and 48 years, respectively.
|
Forty-seven (26.1%) of 180 seropositive patients had antibodies to two or more tick-borne agents. Exposure to B. microti and B. burgdorferi (n = 20 persons) was most prevalent, followed by dual infections with E. equi and B. burgdorferi (n = 10). Nine persons produced antibodies to E. equi and E. chaffeensis alone or in combination with either B. burgdorferi or B. microti. Titers to the ehrlichiae were 2- to 64-fold higher than those to B. microti or B. burgdorferi in six subjects. There was no difference in titers for two persons who had antibodies to E. equi and E. chaffeensis. However, sera from another patient had E. chaffeensis-reactive antibodies at 8- to 16-fold higher concentrations (titers, 1:640 and 1:1,280) than to E. equi (titer, 1:80). There was evidence of single infections in 133 patients, but no persons had antibodies to all four pathogens. Those who had been exposed to multiple agents lived in towns located mainly in southern Connecticut, areas where I. scapularis ticks are most abundant.
Antibodies to B. burgdorferi were present along with those to E. equi or B. microti, or both. Forty serum specimens from this group were selected to be tested by a polyvalent ELISA for reactivity to OspC, OspE, and OspF of B. burgdorferi. Twenty-eight samples (70%) reacted positively to one or more of these highly specific recombinant antigens. Seropositivity was nearly twofold higher than the seropositivities recorded for 15 of 37 serum samples (40.5% positivity) selected from a group of 138 specimens that had antibodies only to whole B. burgdorferi cells. Seropositivities for antibodies to OspC (40.5 to 70% positivity) greatly exceeded seropositivities for antibodies to OspF (2.7 to 17.5% positivity) for both test groups. Titration endpoints ranged from 1:160 to 1:40,960 and from 1:160 to 1:5,120 for serum samples seropositive for antibodies to OspC and OspF, respectively. There were no positive reactions for antibodies to OspE in either group of sera.
In analyses of paired sera, 38 seroconversions and 14 reversions were recorded. Fourfold or greater rises in titration endpoints were noted for 19 patients with Lyme borreliosis. Fewer seroconversions were recorded for patients with HGE (n = 12) and babesiosis (n = 7). Changes in antibody titers occurred in 5 to 53 days for patients with HGE infections, 5 to 161 days for patients with Lyme borreliosis, and 33 to 56 days for patients with babesiosis. Reversions in serologic reactivity occurred in 21 to 271 days for four HGE patients, whereas serologic reactivity occurred in 4 to 131 days for five patients with Lyme borreliosis and 18 to 148 days for four patients with babesiosis. The greatest rise in total antibody titers (negative to 1:20,480) occurred in two patients with Lyme borreliosis in 15 and 19 days, while the greatest decline in antibody titer (1:1,280 to negative) was recorded for a patient with B. burgdorferi infection in 75 days. Records on antibiotic treatment relative to the times that blood samples were collected were incomplete or unavailable.
Western blot analyses were conducted to assess the accuracy of IFA staining methods for the detection of HGE infections. Of the 19 serum specimens from 19 patients confirmed as having HGE by IFA staining procedures, 15 (78.9%) serum specimens had antibodies that reacted with the 44-kDa protein of the HGE agent in immunoblots (Fig. 1). Two additional positive control serum samples were reactive in both assays. There was no reactivity to uninfected HL-60 cells (negative controls). Furthermore, immunoblots revealed no antibodies to the HGE agent in 30 (96.8%) of 31 serum samples found to be negative by IFA staining methods. This group included sera from persons who had rheumatoid arthritis, syphilis, or Lyme borreliosis. A serum sample from a patient who had Lyme borreliosis was negative by IFA staining methods with the BDS strain of E. equi but was positive by immunoblotting (44-kDa band only) with the NCH-1 strain of the HGE agent. When retested by IFA staining methods with the NCH-1 strain, the results were negative, suggesting that the differences are due to experimental techniques rather than antigenic variation. A sufficient amount of serum was available for further testing of one of the four samples found to be positive by IFA staining with the BDS strain and negative by immunoblotting with the NCH-1 strain (Fig. 1, lane 8). When the latter strain was included in tests performed by IFA staining methods, the sample was positive for antibodies at a titer of 1:160, again indicating differences due to methodologies.
|
Serologic analyses for class-specific IgM and IgG antibodies to E. equi and B. burgdorferi revealed differences in seropositivity. We tested at least 24 specimens from individuals in each of three study groups in which persons had leukopenia (1.0 × 109 to 4.0 × 109/liter) or thrombocytopenia (9.0 × 109 to 148 × 109/liter), or both disorders (Table 3). In tests for E. equi antibodies, 3 (1.2%) of 250 serum samples from persons who had low leukocyte and platelet counts had IgM antibodies. Human IgG antibodies were detected in sera from each study group. The proportions ranged from 2.5 to 10.9%. In serologic analyses for Lyme borreliosis, relatively higher numbers of serum samples contained IgM antibodies; the values ranged from 67.6 to 82.1%. Similarly, the proportions of seropositive specimens with IgG antibodies were high (57.8 to 75%).
|
In separate analyses, sera containing IgM or IgG antibodies to whole B. burgdorferi cells were retested by ELISAs containing recombinant antigens of this bacterium. Sera in each study group had class-specific antibodies to one or more Osps or p41-G (Table 4). The proportions of positive serum samples ranged from 46.7 to 67.7% when samples were screened for IgM antibodies to OspC. In analyses for IgG antibodies, seroreactivity to this recombinant antigen was likewise recorded in each of the three study groups; the proportions of positive sera ranged from 31.3 to 63.6%. There was evidence of IgM or IgG antibodies to OspE, OspF, and p41-G, but the rate of seropositivity was usually less than that noted for antibodies to OspC.
|
| |
DISCUSSION |
|---|
|
|
|---|
Serologic analyses provided evidence of HGE and HME in Connecticut. However, when considering that all persons had marked leukopenia or thrombocytopenia, the prevalence of human ehrlichiosis was relatively low. The putative tick vector of the HGE agent, I. scapularis, is found throughout most of Connecticut. By using PCR procedures, 50% of the 118 female I. scapularis ticks from southern Connecticut analyzed carried the DNA of the HGE agent (19). An infection rate of 53% was recorded for female I. scapularis ticks in Westchester County, N.Y. (25), but lower rates (10 to 15%) were reported for Massachusetts, Rhode Island, and Wisconsin (23, 27, 31). Similar DNA analyses revealed no evidence of E. chaffeensis in Connecticut ticks (19). On the basis of the relatively low number of serologically confirmed HGE cases, it appears that the tick transmission rate for this pathogen is low in Connecticut. We also suspect that most persons in the present study probably had other disorders unrelated to tick bites and note that patients who have Lyme borreliosis rarely present with leukopenia or thrombocytopenia. Nonetheless, our results on granulocytic ehrlichiosis agree with those reported earlier, which documented this disease in humans and horses in Connecticut (8, 9, 13).
Although physicians suspected HGE, there was serologic evidence of HME, Lyme borreliosis, and babesiosis in some patients. It is possible that E. chaffeensis infects persons in the northeastern United States, but well-documented cases with supportive results from culture or PCR analyses are lacking there. This disease occurs more frequently in the southern United States, where the lone star tick (Amblyomma americanum) is abundant (28, 29). As observed before (17, 22), some serum samples contained antibodies to E. equi and E. chaffeensis. In our experience (17), there was little or no cross-reactivity between these organisms or with B. microti and B. burgdorferi. Furthermore, sera from 133 (73.9%) of 180 seropositive patients in the present study contained antibodies to a single organism, and sera from persons who had syphilis, rheumatoid arthritis, or babesiosis did not cross-react in tests for HGE. We recognize that persons who had antibodies to E. chaffeensis could have been infected in other states. Future studies should focus on the isolation and identification of ehrlichiae from ticks and wild mammals to determine if E. chaffeensis occurs in New England and if there are other unknown pathogens that might share antigens with the HGE agent and E. chaffeensis. Illnesses in patients who had antibodies to B. burgdorferi and B. microti were probably undiagnosed in many instances. Also, subclinical forms of Lyme borreliosis and babesiosis have been reported (7, 12, 26). It is unclear if persons who had antibodies to these unrelated pathogens had concurrent infections or if they had been exposed to different organisms over extended periods of time. More precise case history information, including isolation data, is needed to verify multiple, active tick-borne infections (21).
Culturing of blood and other tissues from field-collected animals has demonstrated simultaneous infections with B. burgdorferi and B. microti in white-footed mice (Peromyscus leucopus) in areas of Connecticut and Rhode Island where I. scapularis abounds (1, 2). Human beings have been infected with B. microti in inland areas of Connecticut (2). In addition, analyses of sera from humans (17, 20) and white-footed mice (16) revealed coexisting antibodies to multiple agents, including the HGE organism. Simultaneous human Lyme borreliosis and granulocytic ehrlichiosis infections have been demonstrated by culture methods in Westchester County, N.Y. (21). Therefore, if one of these diseases is suspected or diagnosed in humans, serologic testing and the use of adjunct laboratory procedures (i.e., examination of stained leukocytes or erythrocytes, culture for the detection of pathogens, or testing for the DNA of the agents) are warranted. Concurrent infections with different pathogens may complicate illnesses, and consequently, the clinical presentation (signs and symptoms) may be unusual for some patients. Finally, knowledge of simultaneous babesiosis and Lyme borreliosis is important for treatment because different antibiotics are required (28, 29).
Class-specific analyses detected IgM and IgG antibodies to E. equi and B. burgdorferi. However, far fewer patients with suspected HGE infections than patients with Lyme borreliosis were seropositive for IgM antibody. As a part of our study of HGE, physicians were required to submit clinical data that indicated whether the patients had leukopenia and/or thrombocytopenia. Consequently, most of the blood samples were collected later in the course of the disease when IgG antibodies were more likely to be present. The detection of IgM antibodies to B. burgdorferi most likely indicates early stages of infection. Documentation of seroconversions for HGE and Lyme borreliosis was especially important because the clinical picture was often unclear for many patients.
Results of Western blot analyses compared favorably with those obtained by IFA staining methods. We attribute the low number of discrepant results to differences in assay sensitivities. We also recognize, however, that serologic results may occasionally vary with the strain of antigen used in the tests. Antigenic diversity occurs among different strains of the HGE agent (3, 33). Nonetheless, the visualization of key banding patterns for proteins with molecular masses of about 40 to 44 kDa was very helpful in our serological confirmation of HGE. Previous investigators have reported on the significance of the 44-kDa immunodominant protein as a highly specific serologic indicator (6, 11, 24, 29) and on other less frequently identified HGE antigens of 40, 65, 80, and greater than 100 kDa (11). As in the laboratory diagnosis of Lyme borreliosis, Western blot analyses can be used to confirm less specific prescreening tests for antibodies to the HGE agent (24). However, additional work is needed to identify other specific proteins and to produce the appropriate monoclonal antibodies so that immunoblotting results for HGE infections can be further validated and standardized.
As in studies of Lyme borreliosis (18), the production of purified, recombinant fusion proteins of the HGE agent might improve the sensitivities and specificities of ELISAs and Western blotting. Our inclusion of highly specific OspC, p41-G, and OspF antigens in ELISAs for Lyme borreliosis was particularly useful in confirming the results of a polyvalent ELISA, which contained whole-cell antigen of B. burgdorferi. The 44-kDa major outer membrane protein of the HGE agent has recently been cloned and expressed (10, 32). Preliminary test results for a limited number of sera indicate high degrees of sensitivity and specificity in a dot blot immunoassay and Western blot analysis, but further evaluations are needed, however, with a larger panel of serum specimens to assess assay performance. Standardization of highly sensitive and specific class-specific ELISAs for HGE would be easier than standardization of IFA staining methods, and with automation, class-specific ELISAs would be more cost-effective than Western blot analyses.
| |
ACKNOWLEDGMENTS |
|---|
We thank Tia Blevins, Bonnie Hamid, Manchuan Chen, and Hong Tao for assistance with the preparation of antigens and performance of the analyses and are grateful to James Meek of Yale University and to James L. Hadler, Matthew L. Cartter, and Elizabeth Hilborn of the Connecticut State Health Department for initiating and coordinating an emerging infectious disease program.
This work was supported, in part, by grants from the Centers for Disease Control and Prevention including the Emerging Infections Program (grants CCU 111188-02, CCU-106581, and HR8/CCH113382-01), the National Institutes of Health (grants PO-1-AI-30548 and AI-49988), the Mathers Foundation, the Arthritis Foundation, and the American Heart Association; federal funds allocated from the Hatch Act; and funds from the State of Connecticut (Charles Goodyear Award). Erol Fikrig is a Pew Scholar, and Richard A. Flavell is an investigator in the Howard Hughes Medical Institute. Jacob W. IJdo is a Daland Fellow of the American Philosophical Society.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Entomology, The Connecticut Agricultural Experiment Station, P.O. Box 1106, New Haven, CT 06504-1106. Phone: (203) 974-8466. Fax: (203) 974-8502. E-mail: louis.magnarelli{at}po.state.ct.us.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Anderson, J. F.,
R. C. Johnson,
L. A. Magnarelli,
F. W. Hyde, and J. E. Myers.
1986.
Peromyscus leucopus and Microtus pennsylvanicus simultaneously infected with Borrelia burgdorferi and Babesia microti.
J. Clin. Microbiol.
23:135-137 |
| 2. |
Anderson, J. F.,
E. D. Mintz,
J. J. Gadbaw, and L. A. Magnarelli.
1991.
Babesia microti, human babesiosis, and Borrelia burgdorferi in Connecticut.
J. Clin. Microbiol.
29:2779-2783 |
| 3. | Asanovich, K. M., J. S. Bakken, J. F. Madigan, M. Aguero-Rosenfeld, G. P. Wormser, and J. S. Dumler. 1997. Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California. J. Infect. Dis. 176:1029-1034[Medline]. |
| 4. |
Bakken, J. S.,
J. Krueth,
C. Wilson-Nordskog,
R. L. Tilden,
K. Asanovich, and J. S. Dumler.
1996.
Clinical and laboratory characteristics of human granulocytic ehrlichiosis.
JAMA
275:199-205 |
| 5. |
Chen, S.-M.,
J. S. Dumler,
J. S. Bakken, and D. H. Walker.
1994.
Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.
J. Clin. Microbiol.
32:589-595 |
| 6. | Dumler, J. S., K. M. Asanovich, J. S. Bakken, P. Richter, R. Kimsey, and J. E. Madigan. 1995. Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic ehrlichia. J. Clin. Microbiol. 33:1098-1103[Abstract]. |
| 7. | Hanrahan, J. P., J. L. Benach, J. L. Coleman, E. M. Bosler, D. L. Morse, D. J. Cameron, R. Edelman, and R. A. Kaslow. 1984. Incidence and cumulative frequency of endemic Lyme disease in a community. J. Infect. Dis. 150:489-496[Medline]. |
| 8. | Hardalo, C. J., V. Quagliarello, and J. S. Dumler. 1995. Human granulocytic ehrlichiosis in Connecticut: report of a fatal case. Clin. Infect. Dis. 21:910-914[Medline]. |
| 9. | Heimer, R., A. Van Andel, G. P. Wormser, and M. L. Wilson. 1997. Propagation of granulocytic Ehrlichia spp. from human and equine sources in HL-60 cells induced to differentiate into functional granulocytes. J. Clin. Microbiol. 35:923-927[Abstract]. |
| 10. | IJdo, J. W., W. Sun, Y. Zhang, L. A. Magnarelli, and E. Fikrig. Cloning of the gene encoding the 44-kilodalton antigen of the agent of human granulocytic ehrlichiosis and characterization of the humoral response. Infect. Immun. 66:3264-3269. |
| 11. | IJdo, J. W., Y. Zhang, E. Hodzic, L. A. Magnarelli, M. L. Wilson, S. R. Telford III, S. W. Barthold, and E. Fikrig. 1997. The early humoral response in human granulocytic ehrlichiosis. J. Infect. Dis. 176:687-692[Medline]. |
| 12. |
Krause, P. J.,
S. R. Telford III,
R. Ryan,
A. B. Hurta,
I. Kwasnik,
S. Luger,
J. Niederman,
M. Gerber, and A. Spielman.
1991.
Geographical and temporal distribution of babesial infection in Connecticut.
J. Clin. Microbiol.
29:1-4 |
| 13. | Madigan, J. E., J. E. Barlough, and J. S. Dumler. 1996. Equine granulocytic ehrlichiosis in Connecticut caused by an agent resembling the human granulocytic ehrlichia. J. Clin. Microbiol. 34:434-435[Abstract]. |
| 14. |
Magnarelli, L. A., and J. F. Anderson.
1988.
Enzyme-linked immunosorbent assays for the detection of class-specific immunoglobulins to Borrelia burgdorferi.
Am. J. Epidemiol.
127:818-825 |
| 15. | Magnarelli, L. A., J. F. Anderson, and R. C. Johnson. 1987. Cross-reactivity in serological tests for Lyme disease and other spirochetal infections. J. Infect. Dis. 156:183-188[Medline]. |
| 16. | Magnarelli, L. A., J. F. Anderson, K. C. Stafford III, and J. S. Dumler. 1997. Antibodies to multiple tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in white-footed mice. J. Wildl. Dis. 33:466-473[Abstract]. |
| 17. | Magnarelli, L. A., J. S. Dumler, J. F. Anderson, R. C. Johnson, and E. Fikrig. 1995. Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. J. Clin. Microbiol. 33:3054-3057[Abstract]. |
| 18. | Magnarelli, L. A., E. Fikrig, S. J. Padula, J. F. Anderson, and R. A. Flavell. 1996. Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of Lyme borreliosis. J. Clin. Microbiol. 34:237-240[Abstract]. |
| 19. | Magnarelli, L. A., K. C. Stafford III, T. N. Mather, M.-T. Yeh, K. D. Horn, and J. S. Dumler. 1995. Hemocytic rickettsia-like organisms in ticks: serologic reactivity with antisera to ehrlichiae and detection of DNA of agent of human granulocytic ehrlichiosis by PCR. J. Clin. Microbiol. 33:2710-2714[Abstract]. |
| 20. | Mitchell, P. D., K. D. Reed, and J. M. Hofkes. 1996. Immunoserologic evidence of coinfection with B. burgdorferi, B. microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J. Clin. Microbiol. 34:44-48[Abstract]. |
| 21. |
Nadelman, R. B.,
H. W. Horowitz,
T.-C. Hsieh,
J. M. Wu,
M. E. Aguero-Rosenfeld,
I. Schwartz,
J. Nowakowski,
S. Varde, and G. P. Wormser.
1997.
Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis.
N. Engl. J. Med.
337:27-30 |
| 22. | Nicholson, W. L., J. A. Comer, J. W. Sumner, C. Gingrich-Baker, R. T. Coughlin, L. A. Magnarelli, J. G. Olson, and J. E. Childs. 1997. An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis. J. Clin. Microbiol. 35:1510-1516[Abstract]. |
| 23. | Pancholi, P., C. P. Kolbert, P. D. Mitchell, K. D. Reed, J. S. Dumler, J. S. Bakken, S. R. Telford III, and D. H. Persing. 1995. Ixodes dammini as a potential vector of human granulocytic ehrlichiosis. J. Infect. Dis. 172:1007-1012[Medline]. |
| 24. |
Ravyn, M. D.,
J. L. Goodman,
C. B. Kodner,
D. K. Westad,
L. A. Coleman,
S. M. Engstrom,
C. M. Nelson, and R. C. Johnson.
1998.
Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates.
J. Clin. Microbiol.
36:1480-1488 |
| 25. |
Schwartz, I.,
D. Fish, and T. J. Daniels.
1997.
Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease.
N. Engl. J. Med.
337:49-50 |
| 26. | Steere, A. C., E. Taylor, M. L. Wilson, J. F. Levine, and A. Spielman. 1986. Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population. J. Infect. Dis. 154:295-300[Medline]. |
| 27. |
Telford, S. R., III,
J. E. Dawson,
P. Katavolos,
C. K. Warner,
C. P. Kolbert, and D. H. Persing.
1996.
Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle.
Proc. Natl. Acad. Sci. USA
93:6209-6214 |
| 28. |
Walker, D. H.,
A. G. Barbour,
J. H. Oliver,
R. S. Lane,
J. S. Dumler,
D. T. Dennis,
D. H. Persing,
A. F. Azad, and E. McSweegan.
1996.
Emerging bacterial zoonotic and vector-borne diseases: ecological and epidemiological factors.
JAMA
275:463-469 |
| 29. | Walker, D. H., and J. S. Dumler. 1996. Emergence of the ehrlichioses as human health problems. Emerg. Infect. Dis. 2:18-29[Medline]. |
| 30. | Wong, S. J., G. S. Brady, and J. S. Dumler. 1997. Serological responses to Ehrlichia equi, Ehrlichia chaffeensis, and Borrelia burgdorferi in patients from New York State. J. Clin. Microbiol. 35:2198-2205[Abstract]. |
| 31. | Yeh, M.-T., T. N. Mather, R. T. Coughlin, C. Gingrich-Baker, J. W. Sumner, and R. F. Massung. 1997. Serologic and molecular detection of granulocytic ehrlichiosis in Rhode Island. J. Clin. Microbiol. 35:944-947[Abstract]. |
| 32. |
Zhi, N.,
N. Ohashi,
Y. Rikihisa,
H. W. Horowitz,
G. P. Wormser, and K. Hechemy.
1998.
Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis.
J. Clin. Microbiol.
36:1666-1673 |
| 33. | Zhi, N., Y. Rikihisa, H. Y. Kim, G. P. Wormser, and H. W. Horowitz. 1997. Comparison of major antigenic proteins of six strains of the human granulocytic ehrlichiosis agent by Western immunoblot analysis. J. Clin. Microbiol. 35:2606-2611[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»